A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]

Table 2 Mean (95% confidence interval) efficacy differences between treatments over 12 weeks

	Etoricoxib vs placebo	Naproxen vs placebo	Etoricoxib vs naproxen
Primary endpoints
Patient global assessment of disease activity (100 mmVAS) ‡	-9.93^* (-12.96,	-10.0^* (-13.7,	0.09 (-3.61, 3.79)
	-6.90)	-6.32)
Investigator global assessment of disease activity (0–4 scale) ‡	-0.43^* (-0.55,	-0.51^* (-0.66,	0.08 (-0.08, 0.24)
	-0.30)	-0.35)
Tender joint count (total 68 joints) ‡	-3.42^* (-4.89,	-3.16^* (-4.96,	-0.26 (-2.05, 1.54)
	-1.94)	-1.36)
Swollen joint count (total 66 joints) ‡	-1.43† (-2.42,	-1.39† (-2.60,	-0.03 (-1.24, 1.17)
	-0.44)	-0.19)
Secondary endpoints
Patient global assessment of pain (100 mm VAS) ‡	-9.62^* (-12.73,	-10.46^* (-14.25,	0.84 (-2.96, 4.63)
	-6.51)	-6.66)
Health Assessment Questionnaire disability (0–3 scale) ‡	-0.20^* (-0.28,	-0.29^* (-0.38,	0.08 (0.00, 0.17)
	-0.13)	-0.20)
Serum C-reactive protein (ratio between treatments)	1.11† (1.00, 1.23)	0.99 (0.87, 1.13)	1.12 (0.99, 1.27)
ACR20 responder criteria (%)	17.83^* (10.55, 25.12)	16.68^* (7.80, 25.57)	1.15 (-7.74, 10.03)
Discontinuation due to lack of efficacy (%)	-12.75^* (-18.42,	-14.71^* (-21.06,	1.97 (-3.67, 7.61)
	-7.07)	-8.37)

Note: Negative values indicate improvement except for ACR20 responder criteria and serum C-reactive protein.
^* The difference vs placebo was significant (p<0.001). † The difference vs placebo was significant (p<0.05). ‡ For these measures, the difference shown is for the least squares mean of the time-weighted average change from baseline over 12 weeks. ACR20 responder criteria and Discontinuations due to lack of efficacy are shown as differences in frequency over the 12-week period. Serum C-reactive protein was calculated as a ratio between treatments over the 12-week treatment period.

ISSN: 2731-4553